Crispr Theraptc (NASDAQ:CRSP) insider Samarth Kulkarni sold 27,154 shares of Crispr Theraptc stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $20.08, for a total value of $545,252.32. Following the transaction, the insider now directly owns 110,893 shares of the company’s stock, valued at $2,226,731.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Crispr Theraptc (CRSP) traded down 0.29% on Thursday, hitting $20.60. The company’s stock had a trading volume of 197,834 shares. The firm’s market cap is $836.17 million. Crispr Theraptc has a 52 week low of $11.63 and a 52 week high of $25.00. The stock’s 50-day moving average price is $17.74 and its 200-day moving average price is $17.59.

Crispr Theraptc (NASDAQ:CRSP) last released its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.06. The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. Crispr Theraptc’s revenue for the quarter was up 350.0% on a year-over-year basis. Equities analysts expect that Crispr Theraptc will post ($2.43) earnings per share for the current fiscal year.

WARNING: “Crispr Theraptc (CRSP) Insider Samarth Kulkarni Sells 27,154 Shares of Stock” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/crispr-theraptc-crsp-insider-samarth-kulkarni-sells-27154-shares-of-stock/1534650.html.

A number of research analysts have issued reports on the company. Cann assumed coverage on Crispr Theraptc in a report on Monday, July 17th. They set a “market perform” rating for the company. Chardan Capital reissued a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th. SunTrust Banks, Inc. assumed coverage on Crispr Theraptc in a report on Thursday, July 13th. They set a “hold” rating and a $16.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $21.92.

A number of hedge funds have recently added to or reduced their stakes in CRSP. IHT Wealth Management LLC acquired a new stake in Crispr Theraptc during the first quarter valued at $110,000. Monashee Investment Management LLC raised its stake in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the period. Paulson & CO. Inc. acquired a new stake in Crispr Theraptc during the first quarter valued at $1,099,000. Wellington Management Group LLP raised its stake in Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the period. Finally, Credit Suisse AG acquired a new stake in Crispr Theraptc during the first quarter valued at $1,742,000. 23.90% of the stock is currently owned by institutional investors and hedge funds.

About Crispr Theraptc

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.